1. Israel Stocks

  2. •

    Finance

  3. •

    Financial conglomerates
Clal Biotechnology Industries Ltd

Clal Biotechnology Industries Ltd

TTASE:CBI
22.10
ILA
+0.10
(+0.45%)
8.08BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.03
0.18
0.19
0.18
0.29
0.08
0.7
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-1.3
-2.81
-0.87
-1.57
-0.19
-0.28
-0.96
0.68
-0.57
-0.39
-0.2
-0.4
-0.08
- -
Free Cash Flow per Basic Share
-1.29
-0.9
-1.16
-0.86
-0.64
-0.57
0.15
-0.23
-0.27
-0.38
-0.05
-0.04
-0.03
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.23
- -
- -
- -
- -
- -
Book Value per Share
7.16
5.06
4.06
2.67
2.44
2.47
1.39
1.9
1.1
0.8
0.63
0.23
0.13
0.86
Tangible Book Value per Share
-5.16
-2.77
-3.55
-2.78
-1.56
-1.5
-0.5
0.41
-0.28
0.8
0.63
0.23
0.13
0.86
Basic Weighted Avg Shares
117
131
136
136
149
159
161
161
158
157
157
157
157
157
Sales/Revenue/Turnover
3
24
25
24
43
13
113
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-3,302.32
-2,762.63
-605.79
-603.32
-191.65
-669.07
-10.98
-5,166.02
-5,645.09
-3,380
-9,789.42
- -
- -
- -
Depreciation Expense
3
4
5
17
15
15
21
24
23
18
1
- -
- -
- -
Net Income, GAAP
-152
-368
-118
-214
-28
-45
-154
109
-90
-62
-31
-62
-13
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
0.06
- -
- -
- -
- -
- -
Profit Margin (%)
-4,391.71
-1,538.29
-466.07
-884.17
-64.18
-352.02
-136.03
52,925.73
-39,992.41
-16,686.49
-29,856.73
- -
- -
- -
Working Capital
134
383
241
123
154
115
96
183
42
14
8
-14
-15
10
LT Debt
118
87
85
78
72
50
7
6
9
35
30
2
1
7
Total Equity
1,381
1,259
1,092
752
808
868
498
514
338
145
121
46
23
154
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
6.24
6.69
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
33.54
-11.29
- -
- -
- -
- -
- -
Return on Common Equity (%)
-16.66
-47.58
-19.23
-46.69
-7.49
-11.51
-49.51
41.15
-37.41
-41.35
-27.55
-91.85
-46.87
- -

Capital Structure

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
ST Debt
- -
2
- -
LT Borrowings
- -
27
- -
LT Finance Leases
8
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
157
157
157
Market Capitalization
114
98
81

Working Capital

ILS

•

in mil. unless spec.
Sep'22
Dec'22
Jun'23
Total Current Assets
12
17
14
Cash, Cash Equivalents & STI
8
13
11
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
3
3
4
Payables & Accruals
- -
- -
- -
ST Debt
- -
2
- -
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-27.57%
-43.99%
-50.45%
Free Cash Flow
-51.81%
-18.09%
-39.02%
Net Income, GAAP
-11.37%
-48.1%
-78.67%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.4
2025
- -
- -
-0.08
2026
- -
- -
- -

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Avraham Matityahu Fischer
Full Time Employees
121
Sector
Finance
Industry
Financial conglomerates
Address
Azrieli Center Tel Aviv TA Israel 67023
IPO Date
May 30, 2007
Website
cbi.co.il
Similar Companies
Strategy Inc (NASDAQ:MSTR)
BitMine Immersion Technologies, Inc. (NYSE:BMNR)
Strive, Inc. (NASDAQ:ASST)
Hyperliquid Strategies Inc (NASDAQ:PURR)
Stablecoin Development Corporation (AMEX:SDEV)
Jio Financial Services Limited (NSE:JIOFIN)
Business
Clal Biotechnology Industries Ltd. (Ticker: CBI.TA) is a biotechnology company primarily engaged in the development, manufacture, and sale of biopharmaceutical products and active pharmaceutical ingredients. The company’s core offerings include recombinant proteins, biosimilars, peptides, vaccines, enzymes, and specialty pharmaceuticals. It operates through various business segments that serve pharmaceutical companies, research institutions, and healthcare providers, with a product portfolio that spans oncology, autoimmune diseases, infectious diseases, and metabolic disorders. Founded in 1935 and headquartered in Petah Tikva, Israel, Clal Biotechnology Industries maintains a global footprint through strategic partnerships, collaborations, and subsidiaries across North America, Europe, and Asia, facilitating product development and commercial distribution. In recent years, CBI has expanded its capabilities through acquisitions and joint ventures, strengthening its presence in biosimilars and advancing proprietary biologics pipelines. Notably, over the past 1-2 years, the company has entered new strategic alliances to enhance research and development throughput, launched next-generation biosimilar candidates, and broadened its manufacturing infrastructure to support commercial scale production. These initiatives align with its strategy to capitalize on the global demand for biosimilar therapeutics and innovative biopharmaceutical solutions. Clal Biotechnology Industries positions itself as a vertically integrated biotech enterprise with comprehensive expertise ranging from early-stage R&D to large-scale manufacturing under GMP conditions. Its product offerings include bulk active pharmaceutical ingredients; finished dosage forms in injectable, oral, and topical formats; contract manufacturing services; and licensing of proprietary biologics. The company targets pharmaceutical and biotechnology firms, healthcare providers, and government health agencies as primary customers. Overall, Clal Biotechnology Industries is a multifaceted biotech company delivering a wide range of biopharmaceutical products and services with recent strategic expansions in partnerships, product pipelines, and manufacturing capacity, headquartered in Israel with significant international operations.